Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component

Neuroscience Letters

Volumn 418, Issue 2, 2007, Pages 181-185

  Perez Pastene, Carolina ^a   Graumann, Rebecca ^a   Díaz Grez, Fernando ^a   Miranda, Marcelo ^b,e   Venegas, Pablo ^b,c   Godoy, Osvaldo Trujillo ^b   Layson, Luis ^d   Villagra, Roque ^b   Matamala, Jose Manuel ^a   Herrera, Luisa ^a   Segura Aguilar, Juan ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b Faculty of Medicine University of Chile ^*  (Chile)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^d HOSPITAL BARROS LUCO TRUDEAU   (Chile)

^e CLÍNICA LAS CONDES   (Chile)

Author keywords

Aminochrome; Dopamine; Glutathione Transferase; Parkinson's disease; Polymorphism

Indexed keywords

CHROMIUM; DOPAMINE; GLUTATHIONE TRANSFERASE M1;

AEROBIC METABOLISM; AGE DISTRIBUTION; ARTICLE; ASTROCYTE; CHILE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRON TRANSPORT; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; POPULATION GENETICS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ASTROCYTES; BRAIN; CHILE; CYTOPROTECTION; DNA MUTATIONAL ANALYSIS; DOPAMINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; INDIANS, SOUTH AMERICAN; MALE; MIDDLE AGED; MUTATION; OXIDATIVE STRESS; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 34247483564     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.03.024     Document Type: Article

References (31)

1. Abou-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7 (2006) 207-219
2. Ahmadi A., Fredrikson M., Jerregard H., Akerback A., Fall P.A., Rannug A., Axelson O., and Soderkvist P. GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. Biochem. Biophys. Res. Commun. 269 (2000) 676-680
3. Arriagada C., Paris I., Sanchez de las Matas M.J., Martinez-Alvarado P., Cardenas S., Castañeda P., Graumann R., Perez-Pastene C., Olea-Azar C., Couve E., Herrero M.T., Caviedes P., and Segura-Aguilar J. On the neurotoxicity of leukoaminochrome o-semiquinone radical derived of dopamine oxidation: mitochondria damage, necrosis and hydroxyl radical formation. Neurobiol. Dis. 16 (2004) 468-477
4. Baez S., Linderson Y., and Segura-Aguilar J. Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem. Mol. Med. 54 (1995) 12-18
5. Baez S., Segura-Aguilar J., Widersten M., Johansson A.S., and Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 324 (1997) 25-28
6. Campbell E., Takahashi Y., Abramovitz M., Peretz M., and Listowsky I. A distinct human testis and brain mu-class glutathione S-transferase. Molecular cloning and characterization of a form present even in individuals lacking hepatic type mu isoenzymes. J. Biol. Chem. 265 (1990) 9188-9193
7. Carlsson A., and Fornstedt B. Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease. Neurology 41 (1991) 50-51
8. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
9. Dagnino-Subiabre A., Cassels B.K., Johansson A.-S., Baez S., Mannervik B., and Segura-Aguilar J. Glutathione transferase M2-2 prevent formation of neurotoxic aminochrome and dopachrome by catalyzing the conjugation of dopamine and dopa ortho-quinone. Biochem. Biophys. Res. Commun 274 (2000) 32-36
10. Deng Y., Newman B., Dunne M.P., Silburn P.A., and Mellick G.D. Case-only study of interactions between genetic polymorphisms of GSTM1, P1, T1 and Z1 and smoking in Parkinson's disease. Neurosci. Lett. 366 (2004) 326-331
11. Emdadul Haque M., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., and Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta 1619 (2003) 39-52
12. Ericson C., Georgievska B., and Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur. J. Neurosci. 22 (2005) 2755-2764
13. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7 (2006) 306-318
14. Hand P.A., Inskip A., Gilford J., Alldersea J., Elexpuru-Camiruaga J., Hayes J.D., Jones P.W., Strange R.C., and Fryer A.A. Allelism at the glutathione S-transferase GSTM3 locus: interactions with GSTM1 and GSTT1 as risk factors for astrocytoma. Carcinogenesis 17 (1996) 1919-1922
15. Hansson L.O., Bolton-Grob R., Widersten M., and Mannervik B. Structural determinants in domain II of human glutathione transferase M2-2 govern the characteristic activities with aminochrome, 2-cyano-1,3-dimethyl-1-nitrosoguanidine, and 1,2-dichloro-4-nitrobenzene. Protein Sci. 8 (1999) 2742-2750
16. Harada S., Fujii C., Hayashi A., and Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem. Biophys. Res. Commun. 288 (2001) 887-892
17. Ishida Y., Nagai A., Kobayashi S., and Kim S.U. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J. Neuropathol. Exp. Neurol. 65 (2006) 66-77
18. Kato H., Kurosaki R., Oki C., and Araki T. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res. 1030 (2004) 66-73
19. Kelada S.N., Stapleton P.L., Farin F.M., Bammler T.K., Eaton D.L., Smith-Weller T., Franklin G.M., Swanson P.D., Longstreth Jr. W.T., and Checkoway H. Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson's disease. Neurosci. Lett. 337 (2003) 5-8
20. Li H.T., Lin D.H., Luo X.Y., Zhang F., Ji L.N., Du H.N., Song G.Q., Hu J., Zhou J.W., and Hu H.Y. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 272 (2005) 3661-3672
21. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., and Lee V.M. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280 (2005) 2129-21212
22. Paris I., Dagnino-Subiabre A., Marcelain K., Bennett L.B., Caviedes P., Caviedes R., Olea-Azar C., and Segura-Aguilar J. Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J. Neurochem. 77 (2001) 519-529
23. Paris I., Martinez-Alvarado P., Perez-Pastene C., Vieira M.N., Olea-Azar C., Raisman-Vozari R., Cardenas S., Graumann R., Caviedes P., and Segura-Aguilar J. Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra. J. Neurochem. 92 (2005) 1021-1032
24. Rahbar A., Kempkes M., Muller T., Reich S., Welter F.L., Meves S., Przuntek H., Bolt H.M., and Kuhn W. Glutathione S-transferase polymorphism in Parkinson's disease. J. Neural Transm. 107 (2000) 331-334
25. Segura-Aguilar J., Bae S., Widersten M., Welch C.J., and Mannervik B. Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J. Biol. Chem. 272 (1997) 5727-5731
26. Segura-Aguilar J., Metodiewa D., and Welch C.J. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1381 (1998) 1-6
27. Smythies J., De Iuliis A., Zanatta L., and Galzigna L. The biochemical basis of Parkinson's disease: the role of catecholamine o-quinones: a review-discussion. Neurotox Res. 4 (2002) 77-81
28. Foley P., and Riederer P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J. Neurol. 247 Suppl. 2 (2000) 82-94
29. Stokes A.H., Freeman W.M., Mitchell S.G., Burnette T.A., Hellmann G.M., and Vrana K.E. Induction of GADD45 and GADD153 in neuroblastoma cells by dopamine-induced toxicity. Neurotoxicology 23 (2002) 675-684
30. Stroombergen M.C., and Waring R.H. Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum. Exp. Toxicol. 18 (1999) 141-145
31. Valenzuela C.Y., Acuna M.P., and Harb Z. Sociogenetic gradient in the Chilean population. Rev. Med. Chil. 115 (1987) 295-299